<DOC>
	<DOCNO>NCT00019019</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : This phase I trial study side effect best dose carboxyamidotriazole paclitaxel treat patient advance solid tumor refractory lymphoma .</brief_summary>
	<brief_title>Carboxyamidotriazole Paclitaxel Treating Patients With Advanced Solid Tumors Refractory Lymphomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose paclitaxel combine carboxyamidotriazole patient advance solid tumor refractory lymphoma . - Determine pharmacokinetics toxicity regimen patient . - Identify diseases combination appear active . OUTLINE : This dose escalation study . Patients receive oral carboxyamidotriazole ( CAI ) daily paclitaxel IV 3 hour day 8 every 3 week thereafter . Course 1 28 day subsequent course 21 day . Treatment continue absence disease progression unacceptable toxicity . Patients achieve complete response receive 2 additional course treatment . Sequential dose escalation CAI follow sequential dose escalation paclitaxel . Dose escalation cohorts 3 6 patient continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboxyamido-triazole</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose solid tumor ( i.e. , breast ovarian epithelial carcinoma ) lymphoma Slides review NCI Laboratory Pathology Failure therapy proven efficacy disease Prior therapy require follow metastatic disease : Melanoma Nonsmall cell lung cancer Renal cell carcinoma No brain metastasis Primary brain tumor ( glioblastoma multiforme ) stable neurologic deficit allow Measurable evaluable disease require Demonstrated physical exam radiograph within 2 week prior initiation treatment OR Elevated PSA associate prostate cancer Other markeronly disease ineligible PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hematocrit least 27 % Hepatic : Liver function test great 2 time upper limit normal Bilirubin normal PT PTT great 1.25 time upper limit normal Clotting parameter normal No concurrent anticoagulants 1 mg warfarin per day prophylaxis Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 45 mL/min No kidney obstruction Cardiovascular : No cardiac conduction defect require antiarrhythmic No evidence myocardial infarction myocardial damage within past 6 month Other : HIV negative No concurrent infection No guaiacpositive stool test No neuropathy great grade I ( unless associate fixeddeficit primary brain tumor ) Not pregnant nursing Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Recovery prior therapy require Biologic therapy : At least 4 week since prior biologic therapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since mitomycin , nitrosoureas , carboplatin ) No progression carboxyamidotriazole paclitaxel At least 6 month treatment relapse Endocrine therapy : At least 4 week since prior hormonal therapy No concurrent corticosteroid except physiologic replacement Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : At least 1 week since prior therapeutic antibiotic Concurrent prophylactic antibiotic allow except imidazole antifungal ( e.g. , ketoconazole , fluconazole ) No concurrent calcium channel blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult craniopharyngioma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult meningioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult pineocytoma</keyword>
	<keyword>adult pineoblastoma</keyword>
	<keyword>adult meningeal hemangiopericytoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>adult choroid plexus tumor</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>